Neutral
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback
ACADIA Pharmaceuticals (ACAD) reported mixed Q1 2026 results with 10% revenue growth but weaker earnings and a setback for trofinetide in Europe. Desp...